Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020)

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2021 Aug 27

PMID 34442199

Citations 20

Authors

Nikola A Ivica

Colin M Young

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor and T-cell receptor (CAR-T/TCR-T) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other types of cancer. In this paper, we look at all available FDA CAR-T/TCR-T clinical trials for the treatment of cancer, and analyze them with respect to different disease tissues, targeted antigens, products, and originator locations. We found that 627 of 1007 registered are currently active and of those 273 (44%) originated in China and 280 (45%) in the US. Our analysis suggests that the rapid increase in the number of clinical trials is driven by the development of different CAR-T products that use a similar therapeutic approach. We coin the term bioparallels to describe such products. Our results suggest that one feature of the CAR-T/TCR-T industry may be a robust response to success and failure of competitor products.

Citing Articles

Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.

Ku K, Tang J, Chen Y, Shi Y Int J Mol Sci. 2024; 25(10).

PMID: 38791398 PMC: 11120994. DOI: 10.3390/ijms25105361.

"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes.

Vadgama S, Pasquini M, Maziarz R, Hu Z, Ray M, Smith H Blood Adv. 2024; 8(13):3519-3527.

PMID: 38662645 PMC: 11261112. DOI: 10.1182/bloodadvances.2023012240.

Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both?.

Ockfen E, Filali L, Pereira Fernandes D, Hoffmann C, Thomas C Front Immunol. 2023; 14:1276602.

PMID: 37869010 PMC: 10585106. DOI: 10.3389/fimmu.2023.1276602.

The U.S. Food and Drug Administration, the mechanism of action, and other considerations for cell-based therapy candidates.

Caplan A Exp Biol Med (Maywood). 2023; 248(13):1173-1180.

PMID: 37632439 PMC: 10583754. DOI: 10.1177/15353702231194250.

CAR T Cell Therapy: A Versatile Living Drug.

De Marco R, Monzo H, Ojala P Int J Mol Sci. 2023; 24(7).

PMID: 37047272 PMC: 10094630. DOI: 10.3390/ijms24076300.

References

Castellarin M, Watanabe K, June C, Kloss C, Posey Jr A . Driving cars to the clinic for solid tumors. Gene Ther. 2018; 25(3):165-175. DOI: 10.1038/s41434-018-0007-x. View

DAloia M, Zizzari I, Sacchetti B, Pierelli L, Alimandi M . CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018; 9(3):282. PMC: 5833816. DOI: 10.1038/s41419-018-0278-6. View

Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J . Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2019; 135(9):597-609. PMC: 7098811. DOI: 10.1182/blood.2019002121. View

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

Zhao L, Cao Y . Engineered T Cell Therapy for Cancer in the Clinic. Front Immunol. 2019; 10:2250. PMC: 6798078. DOI: 10.3389/fimmu.2019.02250. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Davenport A, Cross R, Watson K, Liao Y, Shi W, Prince H . Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci U S A. 2018; 115(9):E2068-E2076. PMC: 5834689. DOI: 10.1073/pnas.1716266115. View

Newick K, OBrien S, Moon E, Albelda S . CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2016; 68:139-152. DOI: 10.1146/annurev-med-062315-120245. View

Stinchcombe J, Majorovits E, Bossi G, Fuller S, Griffiths G . Centrosome polarization delivers secretory granules to the immunological synapse. Nature. 2006; 443(7110):462-5. DOI: 10.1038/nature05071. View

10.

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

11.

Martinez-Lostao L, Anel A, Pardo J . How Do Cytotoxic Lymphocytes Kill Cancer Cells?. Clin Cancer Res. 2015; 21(22):5047-56. DOI: 10.1158/1078-0432.CCR-15-0685. View

12.

Razpotnik R, Novak N, Serbec V, Rajcevic U . Targeting Malignant Brain Tumors with Antibodies. Front Immunol. 2017; 8:1181. PMC: 5622144. DOI: 10.3389/fimmu.2017.01181. View

13.

Linette G, Stadtmauer E, Maus M, Rapoport A, Levine B, Emery L . Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122(6):863-71. PMC: 3743463. DOI: 10.1182/blood-2013-03-490565. View

14.

Kaida-Yip F, Deshpande K, Saran T, Vyas D . Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018; 6(8):161-166. PMC: 6107532. DOI: 10.12998/wjcc.v6.i8.161. View

15.

Tai Y, Anderson K . Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015; 7(11):1187-99. PMC: 4976846. DOI: 10.2217/imt.15.77. View

16.

Parkhurst M, Yang J, Langan R, Dudley M, Nathan D, Feldman S . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2010; 19(3):620-6. PMC: 3048186. DOI: 10.1038/mt.2010.272. View

17.

Morgan R, Johnson L, Davis J, Zheng Z, Woolard K, Reap E . Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012; 23(10):1043-53. PMC: 3472555. DOI: 10.1089/hum.2012.041. View

18.

Moore C . Biosimilar monoclonal antibodies (mAbs) in oncology. Br J Nurs. 2017; 26(16):S26-S32. DOI: 10.12968/bjon.2017.26.16.S26. View

19.

Zhang J, Wang L . The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. Technol Cancer Res Treat. 2019; 18:1533033819831068. PMC: 6391541. DOI: 10.1177/1533033819831068. View

20.

Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz C . Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017; 9(9):1183-1197. PMC: 5582407. DOI: 10.15252/emmm.201607485. View